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Abstract: 
Background: The highest priority in preventive cardiology is given to patients with 
established coronary artery disease (CAD). The aim of the study was to assess the current 
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implementation of the guidelines for secondary prevention in everyday clinical practice by 
evaluating control of the main risk factors and the cardioprotective medication prescription 
rates in patients following hospitalization for CAD. 
Methods: Fourteen departments of cardiology participated in the study. Patients (aged ≤ 80 
years) hospitalized due an acute coronary syndrome or for a myocardial revascularization 
procedure were recruited and interviewed 6–18 months after the hospitalization. 
Results: Overall, 947 patients were examined 6–18 months after hospitalization. The 
proportion of patients with high blood pressure (≥ 140/90 mmHg) was 42%, with high low-
density lipoprotein cholesterol (LDL-C ≥ 1.8 mmol/L) 62%, and with high fasting glucose (≥ 
7.0 mmol/L) 22%, 17% of participants were smokers and 42% were obese. The proportion of 
patients taking an antiplatelet agent 6–18 months after hospitalization was 93%, beta-blocker 
89%, angiotensin converting enzyme inhibitor or  sartan 86%, and a lipid-lowering drug 90%. 
Only 2.3% patients had controlled all the 5 main risk factors well (non-smoking, blood 
pressure < 140/90 mmHg, LDL-C < 1.8 mmol/L and glucose < 7.0 mmol/L, body mass index 
< 25 kg/m2), while 17.9% had 1 out of 5, 40.9% had 2 out of 5, and 29% had 3 out of 5 risk 
factors uncontrolled. 
Conclusions: The documented multicenter survey provides evidence that there is 
considerable potential for further reductions of cardiovascular risk in CAD patients in Poland. 
A revision of the state funded cardiac prevention programs seems rational. 
Key words: coronary artery disease, risk factors, secondary prevention, smoking, 
hypertension, hypercholesterolemia 
 
 
INTRODUCTION 
Coronary artery disease (CAD) is the single most common cause of death [1]. In 
recent years, a rapid development has been observed in pharmacological and invasive CAD 
treatment methods. Nevertheless, among acute myocardial infarction (MI) survivors, the one-
year mortality rate following discharge from hospital in Poland is about 10% [2]. Several 
causes of this high mortality rate have been indicated, including inadequate lifestyle changes 
and poor control of risk factors, as well as inadequate pharmacotherapy [3]. Indeed, several 
surveys showed a considerable potential for further improvement in the field of secondary 
prevention in European countries, including Poland [4–7]. Interestingly, available data 
suggest beneficial trends in the control of some risk factors, while an adverse trend in others 
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[8]. The guidelines regarding the management of risk factors have recently been updated [9–
12], but little is known about what their impact was of on clinical practice in Poland.  
The aim of the present study was to assess the implementation of recently published 
guidelines for secondary prevention in everyday clinical practice by assessing control of the 
main risk factors and the cardioprotective medication prescription rates in patients after 
hospitalization for CAD. 
 
METHODS 
This study was carried out in 4 regions: one in the northern part of Poland, one in the 
central region and two in the south of the country. In each region, at least one teaching 
hospital and one municipal hospital took part in the survey. In total, 14 departments of 
cardiology from 12 different hospitals participated in the study. Seven departments were 
located in teaching and 7 in municipal hospitals. In each department medical records of 
consecutive patients hospitalized due to acute MI (with and without ST elevation), unstable 
angina, percutaneous coronary intervention (PCI) or scheduled for coronary artery bypass 
grafting (CABG) were reviewed and patients aged ≤ 80 years were identified retrospectively, 
excluding those who  died during their in-hospital stay. If a patient was hospitalized more 
than once within the study period, only the first hospitalization was accepted as an index 
event. Centrally trained research staff undertook data collection using standardized methods 
and the same instruments in all centers. They reviewed patient medical notes, interviewed and 
examined the patients.  
Participants were invited to take part in follow-up examinations 6 to 18 months after 
being discharged. Data on demographic characteristics, personal history of CAD, smoking 
status, blood pressure, fasting glucose, plasma lipids, and prescribed medications were 
obtained using a standardized data collection form. Smoking status was verified by the 
concentration of breath carbon monoxide using a smoker analyzer (Bedfont Scientific, Model 
Micro+). Persistent smoking was defined as smoking at the time of the interview among those 
who smoked during the month prior to the index event.  
Patient height and weight were measured in a standing position without shoes or heavy 
outer garments, using standard scales with a vertical ruler (SECA). Body mass index (BMI) 
was calculated according to the following formula: BMI = weight [kg]/ (height [m])2. Waist 
circumference was measured using a metal tape horizontally in the mid-axillary line, midway 
between the lowest rim of the rib cage and the tip of the hip bone with the patient standing. 
Blood pressure was measured twice, on the right arm in a sitting position after at least 5 min 
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of rest. For plasma lipid and glucose measurements a fasting venous blood sample was taken 
in the morning. For the present report, results of the analyses were done no later than 4 h after 
blood collection. was  
The secondary prevention coefficient was calculated in the following way: for each 
controlled risk factor (non-smoking, blood pressure < 140/90 mmHg, low density lipoprotein 
cholesterol [LDL-C] < 1.8 mmol/L, glucose < 7.0 mmol/L, BMI < 25 kg/m2) during follow-
up examination one point was given. Additionally, one point was given for taking an 
antiplatelet agent and an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II 
receptor antagonist. Thus, the secondary prevention coefficient could vary from 0 to 7. The 
survey protocol was approved by the institutional Bioethics Committees.  
 
Data management 
All data were collected electronically through web-based data entry using a unique 
identification number for the center and individual. Data were submitted via the Internet to the 
data management center where checks for completeness, internal consistency and accuracy 
were run. 
 
Statistical analysis 
Categorical variables were reported as percentages and continuous variables as means 
± standard deviation. The Pearson χ2 test was applied to all categorical variables. Normally 
distributed continuous variables were compared by using the Student t test or analysis of 
variance. Variables without normal distributions were evaluated using the Mann–Whitney U 
test or the Kruskal–Wallis analysis of variance. A two-tailed p value of less than 0.05 was 
regarded as indicating statistical significance.  
 
RESULTS 
The medical records of 1148 patients were reviewed and included in the analyses, 
among them 840 (73.2%) were hospitalized in teaching and 308 (26.8%) in municipal 
hospitals. Characteristics of the study population are presented in Table 1. Patients from the 
ST-elevation MI (STEMI) group were the youngest, and the proportion of women was highest 
in the unstable angina group.  
Cardioprotective drug prescription rates at discharge are shown in Table 2. The 
prescription rate of antiplatelet drugs, ACEI or angiotensin II receptor antagonists, calcium 
antagonists, diuretics, lipid-lowering drugs, and antidiabetic drugs differed between the index 
5 
 
diagnoses  and the prescription rate of anticoagulants was similar across all groups. Among 
patients hospitalized due to acute coronary syndrome 80.0% were prescribed two antiplatelet 
drugs at discharge, the highest proportion were among patients with STEMI and the lowest 
proportion among patients with the unstable group (p < 0.001). Acenocumarol or warfarin 
were prescribed to 5.1% of discharged patients, while heparin (including low-molecular-
weight heparins) was prescribed to 3.8% of patients. New oral anticoagulants were prescribed 
to 7.8% of discharged patients. Overall, 98.9% of patients were prescribed at least one 
antiplatelet drug or anticoagulant, with a variation across groups of borderline significance 
(98.8% in STEMI, 97.3% in non-ST elevation MI [NSTEMI], 97.3% in the unstable angina 
group, 99.8% in PCI, and 100,0% in CABG group, p = 0.05). ACEIs were prescribed to 
78.0% of discharged patients and angiotensin II receptor antagonists to 10.8% of patients. 
Insulin was prescribed to 10.0% of discharged patients, whereas oral antidiabetic drugs were 
prescribed to 25.3% of patients, including metformin, which was prescribed to 23.2% of 
patients.  
Out of the 1148 invited patients, 947 participated in the follow-up examination 6–18 
months after being discharged from hospital. The mean period of time from discharge to the 
follow-up examination was 1.01 ± 0.30 years (in 52% of cases the period was greater than 1 
year). Out of all participants, 16.1% declared that they were smokers. Additionally, 0.8% 
declared that they do not smoke, however, they had an increased concentration of breath 
carbon monoxide (> 10 ppm). Overall, 16.9% of the study participants were smokers. The 
smoking rate differed significantly across groups, the highest being in the ST-elevation group 
(Table 3). Among patients who smoked during the prior month before the index event, 55.8% 
were smoking 6–18 months after being discharged, with no significant difference between the 
groups (STEMI group: 46.7%, NSTEMI group: 56.3%, unstable angina group: 53.9%, PCI 
group: 61.5%, CABG group: 66.7%; p = NS). It was observed that 41.7% of participants had 
high blood pressure, 62.0% had high LDL-C level, 21.5% had fasting glucose ≥ 7.0 mmol/L, 
41.9% were obese while 85.1% were overweight or obese 6–18 months after being 
discharged. Mean systolic blood pressure was 134.3 ± 20.3 mmHg, diastolic blood pressure 
was 79.9 ± 11.5 mmHg, mean LDL-C level was 2.18 ± 0.94 mmol/L, mean BMI was 29.5 ± 
4.5 kg/m2 and mean waist circumference 103.5 ± 11.7 cm in men and 100.0 ± 12.4 cm in 
women.  
The majority of persistent smokers did not attempt to quit smoking following the 
index hospitalization (Table 4). Less than one in seven participants was physically active at 
the recommended level, and about half of the obese patients had attempted to lose weight.  
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The proportion of patients taking antiplatelets, ACEIs/angiotensin II receptor 
antagonists, diuretics, lipid-lowering drugs, and antidiabetic agents at the time of the follow-
up examination differed significantly between the indexed groups (Table 5). Acenocumarol or 
warfarin were prescribed to 5.4% of patients, low-molecular-weight heparins to 0.2% of 
patients, while 8.6% of patients were prescribed new oral anticoagulants. Overall, 97.0% of 
patients were prescribed at least one antiplatelet drug or anticoagulant, with a variation across 
groups of a borderline significance (94.9% in STEMI group, 98.0% in NSTEMI group, 94.9% 
in unstable angina group, 99.3% in PCI, and 100,0% in CABG group, p = 0.05). ACEIs were 
prescribed to 70.5% of patients and angiotensin II receptor antagonists to 15.4% of patients. 
Among all patients, 9.9% were prescribed insulin, whereas 30.4% were prescribed oral 
antidiabetic drugs, including metformin, which was prescribed to 28.3% of patients. A statin 
in combination with ezetimibe was prescribed to 2.3% whereas high dose statin in 
combination with ezetimibe to 1.8% of patients. A statin in combination with a fibrate was 
prescribed to 3.3% whereas high dose statin in combination with a fibrate to 1.8% of patients. 
The mean secondary prevention coefficient was 4.52 ± 1.06 (median value: 5; 
interquartile range: 4, 5). Its value was equal to 7 in only 1.6% of patients, while 17.1% had a 
secondary prevention coefficient of at least 6 (Fig. 1). The secondary prevention coefficient 
value was related to age, employment and the specialization of the physician who, according 
to the patient, had decided about their management (Table 6). The secondary prevention 
coefficient was not related to sex, education, index diagnosis or hospitalization teaching 
hospitals. It was observed that only 2.3% of patients had all main risk factors well controlled 
(non-smoking, blood pressure < 140/90 mmHg, LDL-C < 1.8 mmol/L, glucose < 7.0 mmol/L, 
BMI < 25 kg/m2), while 18.0% had 1 out of 5, 40.8% had 2 out of 5, and 29.0% had 3 out of 5 
risk factors uncontrolled. Finally, 0.9% of study participants had all main risk factors 
uncontrolled.  
 
DISCUSSION 
In general, results suggest a considerable potential for further reduction of 
cardiovascular risk in CAD patients. Recently, not much data concerning the quality of 
secondary prevention of CAD in Poland has been published. In a nation-wide registry of 
patients hospitalized due to MI, the prescription rate of statins, beta-blockers and ACEIs was 
comparable to results obtained in this study, whereas the prescription rate of antiplatelet drugs 
was slightly lower [13]. In a single center analysis of patients undergoing CABG, the use of 
antiplatelets, ACEIs or angiotensin II receptor antagonists and statins were slightly lower 
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when compared to prescription rates in the CABG group in the present study [14]. 
Furthermore, two surveys, which included patients hospitalized due to CAD in 2011–2013 
showed very similar prescription rates at discharge, and significantly lower cardioprotective 
drug usage in the post discharge period compared to the present study [15, 16]. The control of 
main cardiovascular risk factors was at similar levels [14, 15]. Results of the EUROASPIRE 
V survey were recently published [5]. Generally, the average control of main risk factors in 81 
centers from 27 countries were worse compared to the results obtained in the present survey 
(e.g. smoking rate 19% vs. 17%, high LDL-C 71% vs. 62%), with the exception of blood 
pressure, which was controlled at a very similar level. Similar conclusions can be drawn from 
a comparison of Polish patients with stable CAD with patients from other European countries 
participating in the CLARIFY registry [17]. 
Although body mass index, waist, and LDL-C level were the worst controlled risk 
factors (Table 3), it should be emphasized that the present results suggest insufficient control 
of all main cardiovascular risk factors. The present results confirm the previous suggestion 
that sex and index diagnosis are not related to the secondary prevention goal achievement in 
clinical practice, at least in Poland [15]. Interestingly, hospitalization in a teaching hospital 
was not significantly related to the secondary prevention coefficient. Results from the present 
study suggest that patients managed by cardiologists achieve the recommended secondary 
prevention goals more often. Although the influence of a number of confounders cannot be 
excluded, including income.  The WOBASZ study also showed specialists more often provide 
preventive support as compared to general practitioners [18]. Although based on the present 
results, a cause-and-effect relationship cannot be proved , it was suggested that cardiologist 
care is associated with lower mortality following acute coronary syndrome [19].  
Organizational interventions for the secondary prevention of CAD have been shown to 
reduce mortality in CAD patients, further, experts of the Polish Cardiac Society have recently 
announced a new organizational system named “Managed care after myocardial infarction” 
[3, 20]. The system consists of four modules: complete revascularization, education and 
rehabilitation program, electrotherapy including ICDs, biventricular pacing when appropriate 
and periodical cardiac consultations, which  last 12 months. It also contains a quality of care 
assessment based on clinical measures (e.g. risk factor control, rate of complete myocardial 
revascularization, etc.), as well as rate of cardiovascular events [3]. Preliminary results of the 
new system are encouraging [21]. 
 
Limitations of the study 
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The present study had some limitations. Firstly, was the inability to assess the impact 
of implementing secondary prevention guidelines on the risk of cardiovascular complications. 
Secondly, participants of the present study were not representative of all CAD patients. 
Participants were limited to those who had experienced an acute CAD event or had undergone 
a revascularization procedure. Therefore, the present results should not be directly applied to 
other CAD patients. Thirdly, only patients aged ≤ 80 years were studied, therefore results 
should not be applied directly to older patients. Fourthly, assessment of risk factor control at 
the discharge from hospital could not be done. Finally, the doses of cardioprotective drugs 
taken by patients were not analyzed. It is possible that blood pressure, lipids, and glucose 
were not controlled in some cases due to insufficient doses of the prescribed drugs. It should 
also be noted that no information on the patient compliance with instructions regarding 
prescriptions was lacking. It is reasonable to suspect that some patients had been taking their 
medications irregularly [22–24]. According to a previously published study patients’ self-
reported drug intake is often misleading, as in over 40% of subjects reporting regular intake of 
prescribed drugs objective assessment did not confirm this statement [25]. However, an 
important advantage of the analysis is that results are not based just on abstracted medical 
record data but on face-to-face interviews and examinations using the same protocol and 
standardized methods and instruments. Therefore, this analysis provides reliable information 
on lifestyle, risk factors, and therapeutic management for secondary prevention of CAD.  
 
CONCLUSIONS 
 This multicentre survey provides evidence that there is a considerable potential for 
further reduction of cardiovascular risk in CAD patients in Poland. A revision of the state 
funded cardiac prevention program seems rational.  
 
Conflict of interest: None declared 
 
References 
1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-
specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: 
a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 
1736–1788. 
9 
 
2. Gierlotka M, Zdrojewski T, Wojtyniak B, et al. Incidence, treatment, in-hospital 
mortality and one-year outcomes of acute myocardial infarction in Poland in 2009–
2012 — nationwide AMI-PL database. Kardiol Pol. 2015: 142–158, doi: 
10.5603/kp.a2014.0213, indexed in Pubmed: 25371307. 
3. Jankowski P, Gąsior M, Gierlotka M, et al. Coordinated care after myocardial 
infarction. The statement of the Polish Cardiac Society and the Agency for Health 
Technology Assessment and Tariff System. Kardiol Pol. 2016: 800–811, doi: 
10.5603/kp.2016.0118, indexed in Pubmed: 27553352. 
4. Kotseva K, Wood D, Bacquer DDe, et al. EUROASPIRE IV: A European Society of 
Cardiology survey on the lifestyle, risk factor and therapeutic management of 
coronary patients from 24 European countries. Eur J Prev Cardiol. 2015; 23(6): 636–
648, doi: 10.1177/2047487315569401. 
5. Kotseva K, Backer GDe, Bacquer DDe, et al. Lifestyle and impact on cardiovascular 
risk factor control in coronary patients across 27 countries: Results from the European 
Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 
2019; 26(8): 824–835, doi: 10.1177/2047487318825350, indexed in Pubmed: 
25687109. 
6. Jankowski P, Czarnecka D, Badacz L, et al. Practice setting and secondary prevention 
of coronary artery disease. Arch Med Sci. 2018; 14(5): 979–987, doi: 
10.5114/aoms.2017.65236, indexed in Pubmed: 30154878. 
7. Kilic S, Sümerkan M, Emren V, et al. Secondary prevention of coronary heart disease 
in elderly population of Turkey: A subgroup analysis of ELDERTURK study. Cardiol 
J. 2019; 26(1): 13–19, doi: 10.5603/cj.a2017.0113, indexed in Pubmed: 28980279. 
8. Kotseva K, Bacquer DDe, Jennings C, et al. Time Trends in Lifestyle, Risk Factor 
Control, and Use of Evidence-Based Medications in Patients With Coronary Heart 
Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999–2013. Global Heart. 
2017; 12(4): 315, doi: 10.1016/j.gheart.2015.11.003, indexed in Pubmed: 26994643. 
9. Piepoli M, Hoes A, Agewall S, et al. 2016 European Guidelines on cardiovascular 
disease prevention in clinical practice. Eur J Prev Cardiol. 2016; 23(11): NP1–NP96, 
doi: 10.1177/2047487316653709, indexed in Pubmed: 27353126. 
10. Banach M, Jankowski P, Jóźwiak J, et al. PoLA/CFPiP/PCS Guidelines for the 
Management of Dyslipidaemias for Family Physicians 2016. Arch Med Sci. 2017; 1: 
1–45, doi: 10.5114/aoms.2017.64712, indexed in Pubmed: 28144253. 
11. Jankowski P, Kawecka-Jaszcz K, Kopeć G, et al. Polish forum for prevention 
guidelines on smoking: update 2017. Kardiol Pol. 2017: 409–411, doi: 
10.5603/kp.2017.0066, indexed in Pubmed: 28421582. 
12. Czarnecka D, Jankowski P, Kopeć G, et al. Polish Forum for Prevention Guidelines on 
Hypertension: update 2017. Kardiol Pol. 2017: 282–285, doi: 10.5603/kp.2017.0055, 
indexed in Pubmed: 28326530. 
13. Gasior M, Gierlotka M, Pyka Ł, et al. Temporal trends in secondary prevention in 
myocardial infarction patients discharged with left ventricular systolic dysfunction in 
Poland. Eur J Prev Cardiol. 2018; 25(9): 960–969, doi: 10.1177/2047487318770830, 
indexed in Pubmed: 29692221. 
14. Szychta W, Majstrak F, Opolski G, et al. Trends in pharmacological therapy of 
patients referred for coronary artery bypass grafting between 2004 and 2008: a single-
centre study. Kardiol Pol. 2015: 1317–1326, doi: 10.5603/kp.a2015.0094, indexed in 
Pubmed: 25987400. 
15. Jankowski P, Czarnecka D, Łysek R, et al. Secondary prevention in patients after 
hospitalisation due to coronary artery disease: what has changed since 2006? Kardiol 
Pol. 2014: 355–362, doi: 10.5603/kp.a2013.0350, indexed in Pubmed: 24408064. 
10 
 
16. Jankowski P, Czarnecka D, Wolfshaut-Wolak R, et al. Secondary prevention of 
coronary artery disease in contemporary clinical practice. Cardiol J. 2015; 22(2): 219–
226, doi: 10.5603/cj.a2014.0066, indexed in Pubmed: 25299500. 
17. Parma Z, Young R, Roleder T, et al. Management strategies and 5-year outcomes in 
Polish patients with stable coronary artery disease in the CLARIFY registry versus 
other European countries. Pol Arch Intern Med. 2019, doi: 10.20452/pamw.14789, 
indexed in Pubmed: 30951032. 
18. Piwońska A, Piotrowski W, Kozela M, et al. Cardiovascular diseases prevention in 
Poland: results of WOBASZ and WOBASZ II studies. Kardiol Pol. 2018: 1534–1541, 
doi: 10.5603/kp.a2018.0154, indexed in Pubmed: 30251243. 
19. Radzimanowski M, Gallowitz C, Müller-Nordhorn J, et al. Physician specialty and 
long-term survival after myocardial infarction — A study including all German 
statutory health insured patients. Int J Cardiol. 2018; 251: 1–7, doi: 
10.1016/j.ijcard.2017.10.048, indexed in Pubmed: 29092757. 
20. Murphy E, Vellinga A, Byrne M, et al. Primary care organisational interventions for 
secondary prevention of ischaemic heart disease: a systematic review and meta-
analysis. Br J Gen Pract. 2015; 65(636): e460–e468, doi: 10.3399/bjgp15x685681, 
indexed in Pubmed: 26120136. 
21. Feusette P, Gierlotka M, Krajewska-Redelbach I, et al. Comprehensive coordinated 
care after myocardial infarction (KOS-Zawał): a patient’s perspective. Kardiol Pol. 
2019; 77(5): 568–570, doi: 10.5603/kp.a2019.0038, indexed in Pubmed: 30835333. 
22. Huber C, Meyer M, Steffel J, et al. Post-myocardial infarction (MI) care: medication 
adherence for secondary prevention after MI in a large real-world population. Clin 
Ther. 2019; 41(1): 107–117, doi: 10.1016/j.clinthera.2018.11.012, indexed in Pubmed: 
30591287. 
23. Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to 
antiplatelet treatment. Kardiol Pol. 2015: 61–67, doi: 10.5603/kp.a2015.0117, indexed 
in Pubmed: 26101025. 
24. Swieczkowski D, Mogielnicki M, Cwalina N, et al. Medication adherence in patients 
after percutaneous coronary intervention due to acute myocardial infarction: From 
research to clinical implications. Cardiol J. 2013, doi: 10.5603/cj.a2016.0048, indexed 
in Pubmed: 27439366. 
25. Kubica A, Kasprzak M, Obonska K, et al. Discrepancies in assessment of adherence to 
antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–
58, doi: 10.1159/000371392, indexed in Pubmed: 25592409. 
 
 
  
11 
 
Table 1. Characteristics of the study population. 
 STEMI NSTEMI UA PCI CABG 
P 
Total 
 N = 166 N = 259 N = 256 N = 413 N = 54 N = 1148 
Age, years ± SD 61.0 ± 10.3 65.6 ± 8.2 66.4 ± 8.1 65.8 ± 7.7 65.7 ± 6.9 < 0.001 64.9 ± 8.4 
Sex: 
  Men 
  Women 
 
74.7% 
25.3% 
 
68.3% 
31.7% 
 
65.2% 
34.8% 
 
72.6% 
27.4% 
 
85.25 
14.8% 
< 0.05 
 
70.9% 
29.1% 
Duration of education*, years ± SD 12.5 ± 3.1 12.2 ± 3.1 12.1 ± 3.0 12.8 ± 3.2 11.7 ± 3.3 < 0.05 12.4 ± 3.1 
Employed* 41.9% 24.2% 28.65 31.0% 32.6% < 0.05 30.7% 
Index hospitalization in teaching 
hospital 
83.2% 82.3% 67.3% 93.8% 100.0% < 0.001 84.1% 
Participation in a rehabilitation program 
following the index hospitalization 
51.5% 36.9% 13.4% 16.2% 48.8% < 0.001 26.4% 
Specialization of the physician*: 
  Cardiologist 
  General 
  Practitioner 
  Diabetologist 
  Other physician 
  No regular check-ups 
 
 
86.6% 
80.6% 
 
9.7% 
1.5% 
1.5% 
 
 
84.1% 
85.6% 
 
9.7% 
2.1% 
0.5% 
 
 
79.3% 
88.5% 
 
12.0% 
4.6% 
2.3% 
 
 
87.1% 
85.7% 
 
10.9% 
3.1% 
0.05 
 
 
90.1% 
90.7% 
 
9.3% 
2.3% 
0.0% 
 
 
0.08 
0.28 
 
0.94 
0.45 
< 0.05 
 
 
84.8% 
85.8% 
 
10.6% 
3.0% 
0.8% 
*Among subjects who participated in the follow-up examination, as declared by the patients; CABG — coronary artery bypass grafting; NSTEMI — non-ST-
elevation myocardial infarction; PCI — percutaneous coronary intervention; SD — standard deviation; STEMI — ST-elevation myocardial infarction; UA — 
unstable angina 
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Table 2. Prescription rates of cardioprotective drugs at discharge. 
 STEMI NSTEMI UA PCI CABG P Total 
Antiplatelets: 
  At least one agent 
  Two agents 
 
98.8% 
94.6% 
 
96.1% 
81.5% 
 
96.5% 
63.7% 
 
99.8% 
95.2% 
 
98.2% 
27.8% 
 
< 0.01 
< 0.001 
 
98.0% 
81.8% 
Beta-blockers 92.8% 87.3% 91.4% 92.7% 96.3% 0.07 91.4% 
ACEI/sartans 84.3% 86.5% 86.3% 94.0% 83.3% < 0.001 88.7% 
Calcium antagonists 7.8% 22.4% 28.9% 35.1% 35.2% < 0.001 26.9% 
Diuretics*  21.1% 41.7% 50.8% 47.9% 57.4% < 0.001 43.7% 
Potassium sparing diuretics 25.9% 20.9% 18.8% 20.6% 14.8% 0.35 20.7% 
Lipid lowering drugs 
  Statins 
  Fibrates 
  Ezetimibe 
92.8% 
92.8% 
0.6% 
0.6% 
91.9% 
91.1% 
1.5% 
1.2% 
92.2% 
91.8% 
5.5% 
2.3% 
97.6% 
97.3% 
5.1% 
1.2% 
98.2% 
98.2% 
0.0% 
1.9% 
< 0.01 
< 0.01 
< 0.01 
0.60 
94.4% 
94.1% 
3.5% 
1.4% 
Antidiabetic agents 20.5% 30.5% 27.7% 38.3% 27.8% < 0.001 31.1% 
Anticoagulants 15.1% 17.0% 16.8% 16.0% 14.8% 0.98 16.2% 
*Thiazides or loop diuretics; ACEI — angiotensin converting enzyme inhibitors; CABG — coronary artery bypass grafting; NSTEMI — non-ST elevation 
myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-elevation myocardial infarction; UA — unstable angina 
  
13 
 
Table 3. Proportions of patients who did not reach treatment goals 6–18 months after discharge. 
 STEMI NSTEMI UA PCI CABG P Total 
Smoking 21.9% 18.7% 10.6% 18.2% 14.0% < 0.05 16.9% 
Blood pressure ≥ 140/90 mmHg 41.9% 46.5% 42.4% 40.7% 23.3% 0.09 41.7% 
LDL-C ≥ 1.8 mmol/L 57.5% 65.0% 66.4% 58.5% 69.8% 0.16 62.0% 
Glucose ≥7.0 mmol/L 19.6% 24.9% 19.4% 21.7% 20.9% 0.70 21.5% 
Body mass index ≥25 kg/m2, % 87.3% 85.8% 87.0% 84.0% 76.9% 0.57 85.1% 
Body mass index ≥ 30 kg/m2 36.6% 47.2% 39.8% 44.1% 26.2% 0.06 41.9% 
Waist ≥ 102 cm in men and ≥ 88 cm in women 57.5% 68.4% 69.6% 63.5% 48.8% < 0.05 64.4% 
CABG — coronary artery bypass grafting; LDL-C — low density lipoprotein cholesterol; NSTEMI — non-ST elevation myocardial infarction; PCI — 
percutaneous coronary intervention; STEMI — ST-elevation myocardial infarction; UA — unstable angina   
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Table 4. Patients’ lifestyles at the time of interview 6–18 months after discharge (as declared by the patients). 
 STEMI NSTEMI UA PCI CABG P  Total 
Persistent smokers having attempted to quit smoking 
since hospital discharge 
6.7% 10.8% 4.3% 10.9% 0.0% 0.76 8.7% 
Obese patients having attempted actively to lose 
weight in last month 
49.0% 52.7% 58.1% 57.1% 45.4% 0.74 55.0% 
Overweight or obese patients having attempted 
actively to lose weight in last month 
41.9% 40.8% 40.1% 43.1% 32.3% 0.80 41.3% 
Patients having regular physical activit 30 min on 
average five times a week 
14.0% 15.2% 12.0% 14.2% 20.9% 0.62 14.2% 
Patients trying to reduce salt intake  65.45 69.2% 66.8% 68.4% 72.1% 0.91 67.9% 
Patients trying to reduce fat intake 73.5% 72.2% 70.1% 75.5% 72.1% 0.70 73.1% 
Patients trying to reduce calories intake 57.4% 58.1% 58.5% 67.5% 67.4% 0.07 62.0% 
Patients trying to increase vegetables and fruits intake 71.3% 71.2% 71.0% 72.7% 81.4% 0.71 72.2% 
CABG — coronary artery bypass grafting; NSTEMI — non-ST elevation myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-
elevation myocardial infarction; UA — unstable angina   
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Table 5. Proportion of patients taking cardioprotective drugs 6–18 months after discharge from the hospital. 
 STEMI  NSTEMI  UA PCI CABG P Total 
Antiplatelets 94.2% 95.0% 88.0% 94.3% 93.0% < 0.05 92.9% 
Beta-blockers 88.3% 87.9% 86.6% 91.8% 95.4% 0.19 89.4% 
ACEI/sartans 81.8% 86.4% 84.8% 90.3% 65.1% < 0.001 85.9% 
Calcium antagonists 15.3% 32.3% 29.5% 34.4% 20.9% < 0.001 29.5% 
Diuretics*  36.5% 53.5% 50.7% 40.8% 67.4% < 0.01 49.0% 
Potassium sparing diuretics 25.7% 28.8% 15.2% 15.3% 27.9% < 0.001 20.2% 
Lipid lowering drugs: 
  Statins 
  Fibrates 
  Ezetimibe 
87.6% 
87.6% 
1.5% 
1.5% 
90.4% 
89.4% 
1.5% 
2.0% 
85.7% 
84.3% 
6.0% 
3.2% 
94.0% 
94.0% 
4.6% 
2.8% 
90.7% 
90.7% 
0.0% 
2.3% 
< 0.05 
< 0.01 
< 0.05 
0.84 
90.3% 
89.8% 
3.6% 
2.5% 
Antidiabetic agents 24.8% 35.9% 31.5% 38.6% 32.6% 0.05 34.1% 
Anticoagulants 8.0 15.2% 14.8% 15.6% 14.0% 0.23 14.15 
*Thiazides or loop diuretics; ACEI — angiotensin converting enzyme inhibitors; CABG — coronary artery bypass grafting; NSTEMI — non-ST elevation 
myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-elevation myocardial infarction; UA — unstable angina 
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Table 6. The secondary prevention coefficient values according to subgroups of patients.  
Subgroup 
Secondary prevention 
coefficient ± standard deviation 
P 
Age [years]: 
  < 60  
  60–70  
  ≥ 70  
 
4.36 ± 1.19 
4.50 ± 0.96 
4.65 ± 1.10 
< 0.01 
Sex: 
  Men  
  Women  
 
4.54 ± 1.05 
4.49 ± 1.09 
0.52 
Duration of education [years]: 
  ≤ 11  
  > 11  
 
4.47 ± 1.05 
4.57 ± 1.07 
0.17 
Index diagnosis: 
  ST-elevation myocardial infarction 
  Non-ST elevation myocardial infarction 
  Unstable angina 
  Percutaneous coronary intervention 
  Coronary artery bypass grafting 
 
4.51 ± 1.11 
4.41 ± 1.09 
4.47 ± 1.01 
4.63 ± 1.06 
4.50 ± 1.04 
0.19 
Index hospitalization in a teaching hospital: 
  Yes 
  No 
 
4.53 ± 1.06 
4.46 ± 1.07 
0.46 
Rehabilitation program following the index 
hospitalization: 
  Participated 
  Not participated 
 
 
4.61 ± 1.01 
4.49 ± 1.08 
0.12 
Specialization of the physician: 
  Cardiologist  
  Other physician 
  No regular health check-ups 
 
4.57 ± 1.06 
4.30 ± 1.05 
4.13 ± 1.13 
< 0.05 
Professionally active 
Professionally inactive 
4.49 ± 1.07 
4.66 ± 1.03 
< 0.05 
Total 4.52 ± 1.06  
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Figure 1. Distribution of the secondary prevention coefficient values. 
 
 
 
 
 
0.3%
2.7%
13.3%
30.6%
35.9%
15.5%
1.6%
0%
10%
20%
30%
40%
1 2 3 4 5 6 7
